Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) is a study to help understand Alzheimer's Disease (AD) better. AD is a brain illness that affects memory and thinking. The study involves 1,070-2,000 participants aged 55-90, including those with normal cognition, mild cognitive impairment (MCI), and mild AD dementia. It will take place at 59 sites in the US and Canada. Participants will undergo tests like brain scans (PET and MRI), cognitive tests, and give samples for up to 5 years. The study aims to find better ways to diagnose and track AD using biomarkers—substances that indicate the presence of a disease.
- Participation involves tests and scans over 5 years.
- No treatment is provided; it's for research purposes.
- Participants must meet specific health criteria.
Participants must not have other major brain diseases and must be willing to have procedures like lumbar punctures. People from previous ADNI studies can join again. The research focuses on improving future treatments for people with AD by studying how the disease progresses.
Study details
NCT02854033
University of Southern California
27 June 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.